SIMULTANEOUS UV METHOD DEVELOPMENT FOR DETERMINATION OF ROTIGOTINE HYDROCHLORIDE AND RASAGILINE MESYLATE

Author:

M. Patel Shivani,L. Jha Lalit,

Abstract

A precise, accurate analytical UV spectroscopic method has been developed for simultaneous estimation of rotigotine hydrochloride and rasagiline mesylate by using first order derivative spectroscopy. 50 µg mL-1 solutions of both drugs were scanned in the range of 200-800 nm and the first order overlain spectra of both drugs to check zero crossing points. Rotigotine hydrochloride showed zero crossing point at 239 nm where and rasagiline mesylate showed at 273 nm. Six-point calibration curves shown linearity in 2-12 µg mL-1 concentration range for rotigotine hydrochloride and 10-60 µg mL-1 concentration range for rasagiline mesylate. Regression equation obtained for both drugs were used further for determination of concentration in accuracy studies and developed product. In bulk drugs, rasagiline mesylate showed recovery of 98.33-100.93 % and rotigotine hydrochloride showed recovery of 101-103 %. The results obtained from analysis were validated according to ICH guidelines and were found at up to the mark.

Publisher

Indian Drug Manufacturers' Association (IDMA)

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference14 articles.

1. 1. ICH Q2 (R1) Validation of analytical procedures: text and methodology., International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. November 2005.

2. 2. Donald m., Jonathan H., and Majella E.: Rotigotine: A first chemical entity for transdermal drug delivery, Eur. J. Pharm. Biopharm.2014, (88) 586-593.

3. 3. Caslake R., Macleod A., Ives N., Stowe. R and Carl C.: monoamine B oxidase inhibitors versus other dopaminergic agents in early Parkinson's disease, Cochrane database of systematic reviews., 2009 (4).

4. 4. Francesc V., Antonio S., Jose.M, Jose Marey, Miguel M., and Angel A.: The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicenter, observational, retrospective, post marketing study, Int. J. Neurosci., 2017, 22:39.

5. 5. Shimon L., Simon H., Amnon H and Philip L.: Rasagiline-a novel MAO B inhibitor in parkinson's disease, Therapeutic and Risk management., 2007, 3(3) 467-474.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3